Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Efficacy and Safety of Reinitiating PD-1 Inhibitors Following Previous Immunotherapy in Older Adults (≥ 60 Years) with Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center
Clinical Scorecard: Efficacy and Safety of Reinitiating PD-1 Inhibitors Following Previous Immunotherapy in Older Adults (≥ 60 Years) with Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center
At a Glance
Category
Detail
Condition
Advanced Non-Small-Cell Lung Cancer
Key Mechanisms
Rechallenge with PD-1 inhibitors after prior immunotherapy
Target Population
Older adults (≥ 60 years) with advanced NSCLC
Care Setting
Real-world clinical practice
Key Highlights
21.4% objective response rate observed with PD-1 inhibitor rechallenge
Median overall survival of 11.3 months reported
Safety profile consistent with known PD-1 inhibitor toxicities
Pneumonitis and hepatic enzyme elevations require close monitoring
Improved overall survival associated with better ECOG performance status
Guideline-Based Recommendations
Diagnosis
Consider age and functional status in the diagnosis of NSCLC in older adults
Management
Rechallenge with PD-1 inhibitors may be considered after prior immunotherapy failure
Monitoring & Follow-up
Close monitoring for pneumonitis and hepatic enzyme elevations during treatment
Risks
Potential for primary resistance to initial immunotherapy
Patient & Prescribing Data
Older adults with advanced NSCLC previously treated with immunotherapy
Rechallenge may yield clinical benefit in selected patients
Clinical Best Practices
Evaluate ECOG performance status prior to rechallenge
Consider treatment-free intervals when planning rechallenge
Monitor for adverse effects associated with PD-1 inhibitors
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
